VDR
Vitamin D3 receptor
As of the edition of 20 October 2026, VDR (vitamin D3 receptor, UniProt P11473) has 17 drugs tested at it and 26 companies on the list, 6 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11473
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 52
- Disease areas
- Nutrition and metabolism; Cancer; Urinary and reproductive; Hormones; Pregnancy and women's health; Bones, joints and muscles; Skin and connective tissue; Immune system
- Registered trials of its drugs
- 1,449
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 10 |
| Went quiet | 4 |
| Stopped | 3 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cholecalciferol | Marketed | Phase 4 | none listed |
| Ergocalciferol | Marketed | Phase 4 | none listed |
| Vitamin e | Marketed | Phase 4 | none listed |
| Calcitriol | Marketed | Phase 4 | none listed |
| Calcipotriene | Marketed | Phase 4 | none listed |
| Paricalcitol | Marketed | Phase 4 | none listed |
| Calcifediol anhydrous | Marketed | Phase 4 | none listed |
| Alfacalcidol | Marketed | Phase 4 | none listed |
| Doxercalciferol | Marketed | Phase 4 | Ends 2028 |
| Pefcalcitol | Stopped | Phase 3 | none listed |
| Eldecalcitol | Marketed | Phase 4 | none listed |
| DP001 | Went quiet | Phase 2 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 6 |
| Engaged | 3 |
| Undetermined | 11 |
| Total on the list | 26 |
The other 23 companies at VDR
In the product26 companies in all; 23 are not named here, and no score is.
See the 26 companies at VDR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.